论文信息 - Abstract CT162: Addition of parsaclisib (INCB050465), a PI3Kδ inhibitor, in patients with suboptimal response to ruxolitinib: A phase 2 study in patients with myelofibrosis - 字舞流文

Abstract CT162: Addition of parsaclisib (INCB050465), a PI3Kδ inhibitor, in patients with suboptimal response to ruxolitinib: A phase 2 study in patients with myelofibrosis

N. Daver | U. Borate | G. Hobbs | M. Kremyanskaya | T. Burn | E. Wang | R. Rampal | A. Yacoub | C. O'Connell | H. Ali | S. Erickson‐Viitanen | A. Assad | F. Zhou